An update from Evgen Pharma ( (GB:TCF) ) is now available.
TheraCryf plc announced that Dr. Helen Kuhlman, the Chief Business Officer, has purchased 1,500,000 Ordinary Shares, increasing her total shareholding to 2,555,744 shares, which represents 0.5% of the company’s issued share capital. This transaction underscores confidence in the company’s strategic direction and may positively impact its market perception, given Dr. Kuhlman’s significant role in the organization.
More about Evgen Pharma
TheraCryf plc is a clinical stage drug development company focusing on oncology and neuropsychiatry. It has a broad clinical and preclinical pipeline targeting conditions such as glioblastoma, neurodevelopmental disorders, addiction, anxiety, and narcolepsy. The company aims to generate compelling data sets for clinical proof of concept and partners with mid-size to large pharmaceutical companies for larger trials and commercialization. TheraCryf collaborates with major universities and hospitals and is headquartered in Alderley Park, Cheshire. It is listed on AIM in London under the ticker symbol TCF.
YTD Price Performance: -47.12%
Average Trading Volume: 1,625,789
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £1.4M
See more data about TCF stock on TipRanks’ Stock Analysis page.